HALOZYME THERAPEUTICS, INC. - Common Stock (HALO)

Q1 2025 13F Holders as of 31 Mar 2025

Type / Class
Equity / Common Stock
Shares outstanding
123,650,000
Total 13F shares
120,400,923
Share change
-2,007,894
Total reported value
$7,681,637,315
Put/Call ratio
35%
Price per share
$63.81
Number of holders
541
Value change
-$91,593,747
Number of buys
306
Number of sells
211

Institutional Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) as of Q1 2025

As of 31 Mar 2025, HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) was held by 541 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 120,400,923 shares. The largest 10 holders included BlackRock, Inc., VANGUARD GROUP INC, STATE STREET CORP, Invesco Ltd., SNYDER CAPITAL MANAGEMENT L P, ALLIANCEBERNSTEIN L.P., GEODE CAPITAL MANAGEMENT, LLC, MACQUARIE GROUP LTD, JPMORGAN CHASE & CO, and BANK OF AMERICA CORP /DE/. This page lists 543 institutional shareholders reporting positions in this security for the Q1 2025 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.